Reaction Biology Awarded NIH R01 Screening Roadmap Grant
News Mar 16, 2006
Reaction Biology Corporation, (RBC), has announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its DiscoveryDot™ High Throughput Screening technology for drug discovery.
The NIH grant is part of the Screening Roadmap, designed to produce chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded.
The grant provides for $1,828,000 in funding over four years. It originates from the National Human Genome Research Institute and funds two specific areas: 1) The further development of RBC's proprietary spray deposition technology for High Throughput Screening reaction activation, and 2) The development of enhanced microarray printing technology for use in RBC's DiscoveryDot™ HTS system and elsewhere.
RBC claims that, the DiscoveryDot™ technology currently is capable of screening up to 6,600 individual reactions at 1 nanolter volume on a 1-by-3 inch glass slide.
3-D Printed Sugar Scaffolds Offer Sweet Solution for Tissue EngineeringNews
University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can’t: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018